Independent comparison · May 2026
Quick answer
Zepbound (tirzepatide) generally produces more weight loss than Wegovy (semaglutide) — clinical trials show 15–22% versus 14.9% body-weight reduction. Zepbound is more expensive at list price but has aggressive 2026 self-pay programs. Both are FDA-approved specifically for chronic weight management, which matters for insurance coverage.
| Attribute | Zepbound | Wegovy |
|---|---|---|
| Generic name | Tirzepatide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA-approved for | Chronic weight management | Chronic weight management |
| Avg weight loss (trials) | 15–22% at 72 weeks | 14.9% at 68 weeks |
| Mechanism | Dual GLP-1 + GIP | GLP-1 only |
| List price | ~$1,086/month | ~$1,349/month |
| Direct cash-pay program | $499/month | $349/month |
Unlike Mounjaro and Ozempic (which are diabetes drugs sometimes used off-label), Zepbound and Wegovy are both FDA-approved specifically for chronic weight management. That changes everything about insurance coverage, prescriber comfort, and patient eligibility.
Eligibility on label is similar: BMI 30 or higher, or BMI 27 with at least one weight-related comorbidity.
On a 200-lb starting body weight, Wegovy's 14.9% average translates to about 30 pounds of loss. Zepbound's 15–22% range translates to 30–44 pounds. The gap is real but the upper end requires staying on the highest dose.
Tolerance varies. Some patients respond more strongly to semaglutide, others to tirzepatide. Many providers start on Wegovy because it is less expensive and has a longer track record, then switch to Zepbound if response stalls.
Wegovy's direct $349/month cash-pay program (introduced in 2024 and expanded in 2026) is the cheapest brand-name path for patients without coverage. Zepbound's $499/month direct program is newer and competitive but priced 40% above Wegovy.
Both are still above the compounded telehealth options. If price is the deciding factor, compounded semaglutide ($99/month at the cheapest legit programs) outcompetes both. If FDA-approval is the deciding factor, Zepbound and Wegovy are the only choices.
Independently rated providers that prescribe these medications, sorted by editorial score.
Comprehensive GLP-1 programs with board-certified physicians and lab monitoring
Excellent
Highest-converting GLP-1 provider — $16 EPC, personalized consultations, tailored prescriptions
Excellent
150K+ members with 5 medication forms — injections, oral drops, lozenges, tablets, and pills
Very Good
On average yes — Zepbound (tirzepatide) shows 15–22% body-weight loss in the SURMOUNT-1 trial versus Wegovy's 14.9% in STEP 1. Individual response varies and direct head-to-head trials are limited.
Coverage is more common than for Mounjaro because Zepbound is FDA-approved for weight management, but plan-by-plan variation is wide. Many employer plans cover it with prior authorization; some plans dropped coverage in 2026.
Yes, with a provider's supervision. Switching requires a fresh prescription and starting at the lowest Zepbound dose, regardless of where you were on Wegovy.